Building on their successful partnership in the United Arab Emirates, Stallergenes SA and Genpharm Services have announced today that they have extended their exclusive agreement to promote and market in Egypt, Stallergenes’ range of allergen-immunotherapy (AIT) treatments. “We are very proud to extend our collaboration over to Egypt, the largest pharmaceutical market in the region with more than 80 million people. Allergic Rhinitis & Allergic Asthma are main concerns and there is an unmet medical need. We are immediately getting to the task of raising awareness starting with a major scientific event next month at Cairo University”, said Karim Smaira, Genpharm’s CEO.
Stallergenes is a European biopharmaceutical company specialized in the treatment by allergen immunotherapy of allergy related respiratory diseases, such as severe rhino-conjunctivitis and rhinitis, as well as allergic asthma. The seventh largest pharmaceutical company in France and the leader in sublingual immunotherapy treatment, Stallergenes devotes almost 20% of its gross turnover to Research & Development and is actively involved in the development of a new therapeutic class, sublingual immunotherapy tablets. In 2011, the company had sales of € 235 million and more than 500,000 patients were treated with Stallergenes products.
About GENPHARM Services
Genpharm Services is a pharmaceutical marketing company, based in the Dubai Biotechnology and Research Park, UAE. Through Evidence based medicine, Genpharm provides healthcare organizations with innovative therapeutic solutions, in niche and rare genetic disease areas, market access strategies and sustainable commercial solutions, in the Middle East and North Africa Region.